News

KeViRx, Inc selected as part of BLUE KNIGHT™ collaboration for global health preparedness

Charlottesville, Virginia – KeViRx, Inc. (“KeViRx”) has been selected to join Blue Knight, a joint initiative between Johnson & Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S. Department of Health and Human Services. 

Blue Knight is a collaborative program designed to anticipate and respond to global health security threats. Blue Knight provides a scientific and technological ecosystem for innovative, early stage startup companies to develop technologies that are strategically aligned with global health interests. KeViRx was selected for this program based on its platform small molecule technology, KVX-053, which displays efficacy in preclinical models of ovarian cancer, acute myeloid leukemia and acute lung injury.  As a Blue Knight company with a footprint at JLABS @ Washington, DC, KeViRx will benefit from dedicated mentorship and unique benefits from BARDA, in addition to access to the Johnson & Johnson Innovation extensive global network of innovators for critical insights centering on KVX-053 development.

“KeViRx is honored to be selected to be a Blue Knight company and we are excited to be working with the Blue Knight program. We are optimistic that the program will help advance our KVX-053 platform for global health applications in the present and the future,” said Dr. John S. Lazo, who serves as KeViRx’s Chief Scientific Officer.

Read more here.

Recent News

03/23/2023

Children’s National Hospital names Michelle Riley-Brown as new CEO to succeed Kurt Newman

The Children’s National Board of Directors announced that Michelle Riley-Brown, MHA, FACHE, has been named as the new president and chief executive officer (CEO) of Children’s National Hospital. On July 1, Riley-Brown will succeed Kurt Newman, M.D. , who is retiring after 11 years as president and CEO. Riley-Brown is an accomplished executive with over

03/21/2023

Mason leads planning study to position Northern Virginia as a premier location for the life science industry

During the past several years, industry demand for a skilled life science workforce has been surging. In Virginia, while there are currently shortages in almost all health-related professions, little is known about whether there is an adequate supply of life science workers to meet the needs of employers. Now George Mason University is working toward

03/21/2023

California invests $50M to partner with Civica Rx on insulin manufacturing

California Gov. Gavin Newsom has announced a new contract with nonprofit drugmaker Civica Rx, a move that brings the state one step closer to creating its own line of insulin to bring down the cost of the drug. Once the medicines are approved by the Food and Drug Administration, Newsom said at a press conference